Solana DeFi Ecosystem: The Double Dilemma of Plummeting Trading Volume and Staking Income

Can the Uniswap Foundation solve the token value capture dilemma through its huge investment plan?

With a trillion-dollar trading volume and an average daily liquidation amount of $400 million, Hyperliquid has become a whale-chain casino

Data interpretation of the current market: Has the opportunity to buy the bottom of Bitcoin arrived?

Taking stock of 6 new Launchpad platform players: What innovative ways of playing are there?

Solanas new proposal sparks controversy in the community: the interest game behind the inflation revolution

A review of seven popular equity NFTs: Backed by high financing, most have not yet issued tokens

Borrowing limits and collateralization rates are rising, what is MakerDAO trying to do by passing an emergency governance proposal?

Decoding DeFi 2025: Ten key insights from consumer finance to technological innovation

Libra hunting moment: nearly 30% of large investors took over at high prices, and more than 70,000 addresses were harvested

The Dark Forest of MEME Coin: With a Retention Rate of One Percent, It’s Hard for Retail Investors to Make Money

When the market is sluggish, here are three profit models that do not rely on market trends

Detailed analysis of Coinbases latest financial report: Full-year revenue will double in 2024, and Q4 will achieve the largest quarterly revenue in thr

Which crypto companies are considering IPOs after Trump took office?

Interpreting the BNB Chain 2025 Roadmap: Anti-MEV Protection, AI Priority, Meme Coin Support

Inventory of 32 BNB Chain ecological projects listed on Binance: the average increase is nearly 26%

Messari: A look at the Decentralized Physical Artificial Intelligence DePAI map

The Agent graduation rate is only 8.3%, and Virtuals encounters unsuitable environment on the first day of Solana launch

AO airdrop weakness and ecological stagnation: Has Arweave’s new “decentralized computing” narrative failed?

Does DeSci need a pump? Talking about the dilemma of the pharmaceutical industry